- Poster presentation
- Open Access
Clinical audit: long-term follow-up of women with genital lichen sclerosus
© Ngu and Green; licensee BioMed Central Ltd. 2012
- Published: 9 July 2012
- Squamous Cell Carcinoma
- General Practitioner
- Skin Cancer
- Topical Corticosteroid
- Information Leaflet
Genital lichen sclerosus (LS) is a chronic inflammatory disease usually managed with intermittent potent topical corticosteroids.5% of women with untreated vulval LS go on to develop squamous cell carcinoma (SCC).
Current guidelines from the British Association of Dermatologists (BAD) state that patients on topical corticosteroids should be reviewed at least annually by their General Practitioner (GP) . Previous work has shown that many women discharged from secondary to primary care are lost to follow-up .
An anonymised questionnaire was sent to sixty women with genital LS discharged from our regional vulval clinic more than a year previously. Caldicott Guardian approval was obtained for the study.
Forty-five patients (75%) returned the questionnaire. Seventy one percent of patients had not attended their GP for follow-up. Of the 17 patients who had seen their GP, only 7 had had their vulval area examined. Only 53% of patients self-examined their vulval area. 48% were not aware of the need to report any area of persistent abnormality to their GP. 28 patients were still using topical corticosteroid - 24 of these potent or ultrapotent steroid. 48.9% of all respondents thought a 30g tube of strong steroid should last a year, 26.7% three months, 13.3% one month and 11.1% were unsure. Only 30 patients (66.7%) were aware of the increased risk of skin cancer associated with vulval LS, the remainder being unaware or uncertain.
Our study has highlighted worrying deficiencies in the long-term follow-up of this patient group. We have devised a brief patient information leaflet to be provided to both the patient and their GP at discharge to detail the small increased cancer risk, the need for monthly self-examination, clear instructions on the use of topical corticosteroids and the need for annual review by their GP. Hopefully, this will lead to an increased quality of patient care. We then plan to repeat the audit after an appropriate time interval.
- Neill SM, Lewis FM, Tatnall FM, NH Cox: British Association of Dermatologists' Guidelines for the Management of Lichen Sclerosus 2010. BJD. 2010, 147 (4): 640-649.View ArticleGoogle Scholar
- Rossi E, Pavanello P, Franchella A: Lichen sclerosus in children with phimosis. Minerva Pediatr. 2007, 59 (6): 761-5.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.